LEPU Test Kit ELISA Anticorpi Neutralizzanti COVID-19

Metodo: ELISA

Principio: Il reagente di rilevamento è realizzato con una tecnologia immunosoppressiva con anticorpi neutralizzanti. Il kit contiene il dominio di legame del recettore 2019-nCoV ricombinante marcato con perossidasi di rafano (RBD-HRP) e il recettore della cellula ospite ACE2 immobilizzato su piastra ELISA.

Per informazioni scrivere a: [email protected]

Manipolazione dei campioni

Campioni: siero o plasma anti-coagulato K2-EDTA

Campioni di siero:

Utilizzare una provetta con separatore di siero per agglutinare i campioni per 30 minuti, quindi centrifugare a 1000 giri per 10 minuti. I campioni devono essere testati immediatamente dopo la raccolta. Quelli che non possono essere testati nell’immediato, possono essere conservati a 2-8°C per 7 giorni oppure a -20°C per non più di 3 mesi.

Plasma anti-coagulato K2-EDTA:

Centrifugare a 1000 giri per 10 minuti dopo la raccolta del sangue.

Fasi operative:

Interpretazione dei risultati:

  • Il valore di tasso di interruzione negativo/positivo dell’anticorpo neutralizzante al COVID-19 è determinato dal tasso di inibizione.

Tasso di inibizione= (1-valore del campione OD/valore negativo del controllo qualità OD) x 100%

(Un valore alto di OD significa più legami ACE2 con RBD)

  • Tasso di inibizione ≥ 20% significa test positivo: l’anticorpo neutralizzante è stato rilevato
  • Tasso di inibizione <20% significa test negativo: non è stato rilevato l’anticorpo neutralizzante a SARS-CoV-2

Strumentazione richiesta per metodo manuale:

  • Lettore di micropiastre a lunghezza d’onda singola (o doppia) con un filtro da 450 nm.
  • Lavatrice automatica per micropiastre
  • Centrifuga
  • Incubatore a temperatura costante (37°C)
  • Refrigeratore per conservare i campioni e i reagenti
  • Puntali e pipette da 10 ul, 200 ul e 1000 ul
  • Pipette multi-canale
  • Acqua demineralizzata o deionizzata per i lavaggi
  • Timer
  • Provette piccole
  • Contenitore monouso per conservare i reagenti
  • Carta assorbente

Strumentazione richiesta per metodo automatico:

  • ELISA200 CE
  • ELISA400 CE

Vantaggi:

  • L’interazione RBD-ACE2 del prodotto può essere neutralizzata da anticorpi neutralizzanti specifici nei sieri di pazienti o animali, allo stesso modo di cVNT o pVNT
  • Alta specificità e sensibilità
  • Può esserci un throughput elevato con dispositivi automatizzati

Svantaggi:

  • Tempi lunghi: 1 ora
  • Passaggi operativi complessi
  • Richiesta attrezzatura

  • SARS-CoV-2 (COVID-19) Nucleocapsid Antibody
    Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6).
    9099-002mg 225.11 EUR

  • SARS-CoV-2 (COVID-19) Nucleocapsid Antibody
    Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6).
    9099-01mg 582.37 EUR

  • SARS-CoV-2 (COVID-19) Nucleocapsid Antibody
    Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6).
    9103-002mg 225.11 EUR

  • SARS-CoV-2 (COVID-19) Nucleocapsid Antibody
    Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6).
    9103-01mg 582.37 EUR

  • SARS-CoV-2 (COVID-19) NSP7 Antibody
    Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP7 plays a role in viral RNA synthesis (3,4,5). It forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers.
    9155-002mg 225.11 EUR

  • SARS-CoV-2 (COVID-19) NSP7 Antibody
    Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP7 plays a role in viral RNA synthesis (3,4,5). It forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers.
    9155-01mg 582.37 EUR